NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Uno, Masaya ^a   Saitoh, Yasunori ^a   Mochida, Kanako ^a   Tsuruyama, Eri ^a   Kiyono, Tohru ^c   Imoto, Issei ^d   Inazawa, Johji ^a   Yuasa, Yasuhito ^b   Kubota, Toshiro ^a   Yamaoka, Shoji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR KAPPA BETA INDUCING KINASE; PROTEIN P52; UNCLASSIFIED DRUG; CYCLIN D1; GELATINASE B; I KAPPA B KINASE; NF-KAPPA B KINASE; NFKB2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; EMBRYO; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN DEPLETION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL TISSUE; CARCINOGENICITY; CELL PROLIFERATION; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; PREDICTIVE VALUE; PROTEIN FUNCTION; REPORTER GENE; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; CELL ADHESION; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; HEK293 CELL LINE; METABOLISM; OVARY TUMOR; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, REPORTER; HEK293 CELLS; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NF-KAPPA B P52 SUBUNIT; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84922333733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone0088347     Document Type: Article

References (41)

1. Romero I, Bast RC Jr (2012) Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy. Endocrinology 153: 1593-1602.
2. Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27: 693-733.
3. Qing G, Qu Z, Xiao G (2005) Stabilization of Basally Translated NF-κBinducing Kinase (NIK) Protein Functions as a Molecular Switch of Processing of NF-κB2 p100. J Biol Chem 280: 40578-82. (Pubitemid 41780547)
4. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, et al. (2008) Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 9: 1364-70.
5. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, et al. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130. (Pubitemid 47199123)
6. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144. (Pubitemid 47208626)
7. Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, et al. (2008) Overexpressed NF-κB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 111: 5118-29.
8. Saitoh Y, Martínez Bruyn VJ, Uota S, Hasegawa A, Yamamoto N, et al. (2010) Overexpression of NF-κB inducing kinase underlies constitutive NF-κB activation in lung cancer cells. Lung Cancer 70: 263-70
9. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, et al. (2003) TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 278: 36005-36012 (Pubitemid 37139919)
10. Okamoto T, Sanda T, Asamitsu K (2007) NF-kappa B signaling and carcinogenesis. Curr Pharm Des 13: 447-62.
11. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, et al. (2010) Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res 70: 4005-14.
12. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ (2000) Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60: 5334-9.
13. Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, et al. (2009) Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol 40: 795-806.
14. Rattan R, Narita K, Chien J, Maguire JL, Shridhar R, et al. (2010) TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappaB pathway. Oncogene 29: 1362-73.
15. Wakana K, Akiyama Y, Aso T, Yuasa Y (2006) Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis. Cancer Lett 241: 281-8. (Pubitemid 44163044)
16. Watanabe T, Imoto I, Kosugi Y, Ishiwata I, Inoue S, et al. (2001) A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 81: 172-7. (Pubitemid 32424156)
17. Kikuchi R, Tsuda H, Kanai Y, Kasamatsu T, Sengoku K, et al. (2007) Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res 67: 7095-105. (Pubitemid 47206536)
18. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, et al. (2004) Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64: 1403-10. (Pubitemid 38235609)
19. Sasaki R, Narisawa-Saito M, Yugawa T, Fujita M, Tashiro H, et al. (2009) Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis 30: 423-31.
20. Israel A, Yano O, Logeat F, Kieran M, Kourilsky P (1989) Two purified factors bind to the same sequence in the enhancer of mouse MHC class I genes: one of them is a positive regulator induced upon differentiation of teratocarcinoma cells. Nucleic Acids Res 17: 5245-5257. (Pubitemid 19173357)
21. Mori N, Fujii M, Iwai K, Ikeda S, Yamasaki Y, et al. (2000) Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells. Blood 95: 3915-3921. (Pubitemid 30412868)
22. Uota S, Zahidunnabi Dewan M, Saitoh Y, Muto S, Itai A, et al. (2012) An IκB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells. Cancer Sci 103: 100-6.
23. Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, et al. (2012) Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell 21: 121-35.
24. Lengyel E, Schmalfeldt B, Konik E, Spä the K, Hä rting K, et al. (2001) Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 82: 291-8. (Pubitemid 32730606)
25. Barbieri F, Lorenzi P, Ragni N, Schettini G, Bruzzo C, et al. (2004) Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology 66: 310-5. (Pubitemid 38822801)
26. Suzuki N, Aoki D, Tamada Y, Susumu N, Orikawa K, et al. (2004) HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells. Gynecol Oncol 95: 290-8. (Pubitemid 39445863)
27. Huang Y, Fan W (2002) IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol 61: 105-13. (Pubitemid 34049517)
28. Yang G, Xiao X, Rosen DG, Cheng X, Wu X, et al. (2011) The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin Cancer Res 17: 2181-94.
29. Ranuncolo SM, Pittaluga S, Evbuomwan MO, Jaffe ES, Lewis BA (2012) Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood 120: 3756-63.
30. Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, et al. (2009) RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res 69: 3267-71.
31. Zhang J, Warren MA, Shoemaker SF, Ip MM (2007) NFkappaB1/p50 is not required for tumor necrosis factor-stimulated growth of primary mammary epithelial cells: implications for NFkappaB2/p52 and RelB. Endocrinology 148: 268-78. (Pubitemid 46021459)
32. Fritz RD, Radziwill G (2010) CNK1 promotes invasion of cancer cells through NF-kappaB-dependent signaling. Mol Cancer Res 8: 395-406.
33. Connelly L, Robinson-Benion C, Chont M, Saint-Jean L, Li H, et al. (2007) A transgenic model reveals important roles for the NF-kappa B alternative pathway (p100/p52) in mammary development and links to tumorigenesis. J Biol Chem 282: 10028-35. (Pubitemid 47104643)
34. Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, et al. (2011) Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 331: 468-72.
35. Yamamoto M, Ito T, Shimizu T, Ishida T, Semba K, et al. (2010) Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer. Cancer Sci 101: 2391-7.
36. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, et al. (2012) Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 3: 1011-25.
37. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, et al. (2009) Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 4: e5311.
38. Frankel A, Man S, Elliott P, Adams J, Kerbel RS (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6: 3719-28.
39. Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, et al. (2009) A phase II evaluation of bortezomib in the treatment of recurrent platinumsensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115: 215-20.
40. Shinkura R, Kitada K, Matsuda F, Tashiro K, Ikuta K, et al. (1999) Alymphoplasia is caused by a point mutation in the mouse gene encoding NF-kappab-inducing kinase. Nat Genet 22: 74-7. (Pubitemid 29214808)
41. Yin L, Wu L, Wesche H, Arthur CD, White JM, et al. (2001) Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science 291: 2162-5. (Pubitemid 32224449)